GW Henssler & Associates Ltd. Cuts Stock Position in Amgen Inc. (NASDAQ:AMGN)

GW Henssler & Associates Ltd. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 90,423 shares of the medical research company's stock after selling 1,373 shares during the period. Amgen accounts for about 1.4% of GW Henssler & Associates Ltd.'s holdings, making the stock its 27th biggest holding. GW Henssler & Associates Ltd.'s holdings in Amgen were worth $23,568,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Centaurus Financial Inc. lifted its holdings in Amgen by 16.8% in the 2nd quarter. Centaurus Financial Inc. now owns 1,615 shares of the medical research company's stock worth $505,000 after buying an additional 232 shares in the last quarter. AMF Tjanstepension AB increased its position in shares of Amgen by 16.9% during the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company's stock worth $38,825,000 after acquiring an additional 17,387 shares during the last quarter. Czech National Bank lifted its stake in shares of Amgen by 7.1% in the third quarter. Czech National Bank now owns 109,459 shares of the medical research company's stock worth $35,269,000 after acquiring an additional 7,237 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Amgen by 25.7% in the third quarter. GAMMA Investing LLC now owns 10,420 shares of the medical research company's stock valued at $3,357,000 after purchasing an additional 2,130 shares during the last quarter. Finally, WealthBridge Capital Management LLC grew its stake in Amgen by 9.4% during the 3rd quarter. WealthBridge Capital Management LLC now owns 1,025 shares of the medical research company's stock valued at $330,000 after purchasing an additional 88 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Sanford C. Bernstein began coverage on Amgen in a research report on Thursday, October 17th. They issued an "outperform" rating and a $380.00 target price on the stock. UBS Group cut their price target on shares of Amgen from $335.00 to $326.00 and set a "neutral" rating on the stock in a report on Thursday, October 31st. Truist Financial decreased their price objective on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Finally, Leerink Partners decreased their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Amgen presently has an average rating of "Hold" and a consensus price target of $314.00.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $285.42 on Monday. The firm's 50 day moving average is $271.06 and its two-hundred day moving average is $304.33. The firm has a market capitalization of $153.42 billion, a P/E ratio of 36.55, a PEG ratio of 2.85 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.34%. This is an increase from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is presently 121.90%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.